Vivo Capital leads over $200m round in Chinese biotech firm Avistone

Vivo Capital leads over $200m round in Chinese biotech firm Avistone

Source: Laurynas Mereckas/Unsplash

Avistone Pharmaceuticals, a Chinese clinical-stage biotech firm focusing on precision oncology therapeutics, has raised over $200 million in a Series A round of financing led by healthcare investment firm Vivo Capital.